Corrigendum to "Reported Adverse Events in a Multicenter Cohort of Patients Ages 6-18 years with Cystic Fibrosis and at Least one F508dek Allele Receiving Elexacaftor/Tezacaftor/Ivacaftor". J Pediatr. 2024 Jun 28; 274:114176

J Pediatr. 2024 Nov:274:114228. doi: 10.1016/j.jpeds.2024.114228. Epub 2024 Aug 28.
No abstract available

Publication types

  • Published Erratum